Shopping Cart 0
Cart Subtotal
AED 0

Asia-Pacific Injectable Drug Delivery Market Analysis, Companies Profiles, Size, Share, Growth, Trends and Forecast to 2025

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
AED 9175

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
AED 11744
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Asia-Pacific injectable drug delivery market is expected to reach USD 220,922.25 million by 2025 from USD 67,319.56 million in 2017, at a CAGR of 13.9% in the forecast period 2018 to 2025.

The major factors contributing to the growth of the market includes factors such rising cases of chronic diseases and due to rising demand of self-injection devices. On the other hand needle stick injuries and infections may hinder the growth of the market.

The key market players for Asia-Pacific injectable drug delivery market are listed below:

Baxter International, Inc.,

Becton Dickinson and Company,

Gerresheimer AG,

Pfizer, Inc.,

Schott AG,

Alkermes Plc.,

Eli Lilly and Company,

Sandoz,

Terumo Corporation,

Teva Pharmaceuticals Industries Ltd.

Ypsomed,

Bespak

The market is further segmented into:

Type

Usage Pattern

End-User

Mode of Administration

Distribution Channel

Application

Geography

The Asia-Pacific injectable drug delivery market is segmented on the basis of type, portability, type, product type, and application, and usage pattern, mode of administration, end user, distribution channel, and geography. The report provides data for 2016 to 2025, 2017 being the current year while 2018 to 2025 is the forecast period for the report.

The Asia-Pacific injectable drug delivery market is segmented based on type into two notable segments; injectable drug delivery device and injectable drug delivery formulation. Injectable drug delivery device market is segmented into conventional injection devices and self-injection devices. The injectable drug delivery formulation is segmented into conventional drug delivery formulation and novel drug delivery formulation. The Injectable drug delivery market is dominated by formulations with 80.0% market share in 2018, growing at a CAGR of 14.0% and will cross USD 178,225.1 million by 2025.

On the basis of application, the market is segmented into autoimmune disease, hormonal disorders, orphan diseases, oncology and others. The autoimmune diseases segment is further sub segmented based on indications into rheumatoid arthritis, multiple sclerosis, Crohn's disease, psoriasis and others. Hormonal disorders are further segmented into indications such as diabetes, antithrombotic therapy, reproductive health diseases, anemia, osteoporosis and others. The Injectable drug delivery market is dominated by hormonal disorders with 49.4% market share in 2018, growing at a CAGR of 13.7% and will cross USD 107,631.3 million by 2025. However, oncology segment is expected to grow at the highest CAGR of 15.0% in the forecast period, and is expected to reach USD 51,374.1 million in 2025 from USD 14,319.8 million in 2017

On the basis of usage pattern, the market is segmented into curative care, immunization and other usage pattern. The Injectable drug delivery market is dominated by curative care with 94.2% market share in 2018, growing at a CAGR of 13.9% and will cross USD 209,048.6 million by 2025.

On the basis of mode of administration, the market is segmented into skin, circulatory/muskoskeletal, organs and central nervous system. The Injectable drug delivery market is dominated by skin with 50.4% market share in 2018, growing at a CAGR of 14.2% and will cross USD 113,780.0 million by 2025.

On the basis of end users, the market is classified into hospitals and clinics, home healthcare, research laboratories, pharmaceutical and biotechnological companies and others. The Injectable drug delivery market is dominated by hospitals & clinics with 58.0% market share in 2018, growing at a CAGR of 14.0% and will cross USD 129,566.3 million by 2025. However, home healthcare settings segment is expected to grow at the highest CAGR of 15.2% in the forecast period, and is expected to reach USD 44,906.7 million in 2025 from USD 12,286.6 million in 2017

On the basis of distribution channel, the market is classified into hospital pharmacies, pharmacy store, and direct tender and online pharmacy. The Injectable drug delivery market is dominated by direct tenders with 75.5% market share in 2018, growing at a CAGR of 14.2% and will cross USD 170,166.5 million by 2025. However, pharmacy stores segment is expected to grow at the highest CAGR of 14.9% in the forecast period, and is expected to reach USD 28,274.5 million in 2025 from USD 7,975.8 million in 2017.

Based on geography, the Asia-Pacific injectable drug delivery market is segmented into geographical regions, such as,

Japan

China

India

South Korea

Australia

Thailand

Malaysia

Singapore

Indonesia

Taiwan

Rest of APAC

Covered in this report

The report covers the present scenario and the growth prospects of the Asia-Pacific injectable drug delivery market for 2018-2025. To calculate the market size, the report considers the revenue generated from the sales of the web conferencing and unified communication and collaboration (UC&C) and video conferencing, secondary resources and doing in-depth company share analysis of major 10 players in the market.

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

READ MORE

Table Of Content

Scope

Table Of Contents

1 Introduction 32

1.1 Overview Of Asia-Pacific Injectable Drug Delivery Market 32

1.2 Currency And Pricing 33

1.3 Limitation 33

1.4 Markets Covered 34

2 Market Segmentation 37

2.1 Markets Covered 37

2.2 Geographic Scope 38

2.3 Years Considered For The Study 39

2.4 Currency And Pricing 39

2.5 Research Methodology 40

2.6 Primary Interviews With Key Opinion Leaders 43

2.7 Secondary Sources 44

2.8 Assumptions 44

3 Market Overview 45

3.1 Drivers 47

3.1.1 Rising Cases Of Chronic Diseases 47

3.1.2 Rising Demand Of Self-Injection Devices 49

3.1.3 Growth Of Biologics Market 49

3.1.4 Technological Advancements And Innovations In Drug Delivery Market 50

3.2 Restraints 51

3.2.1 Needlestick Injuries And Infections 51

3.2.2 High Cost Of Development 52

3.2.3 Strict Regulatory Framework 53

3.3 Opportunity 54

3.3.1 Increasing Demand For Generic And Biosimilar Drugs 54

3.3.1.1 Generics 54

3.3.1.2 Biosimilars 54

3.3.2 Increasing Demand For Contraceptive Injectables 55

3.3.3 Increasing Demand For Self-Administration Of Drugs 56

3.4 Challenges 57

3.4.1 Alternative Route Of Drug Administration 57

3.4.2 Product Recall 58

3.4.3 Stability Of Products 58

3.4.4 Sterility Of Injections 59

4 Executive Summary 60

5 Premium Insights 62

6 Asia-Pacific Injectable Drug Delivery Market, By Type 65

6.1 Overview 66

6.2 Injectable Drug Delivery Devices 67

6.2.1 Conventional Injection Devices 68

6.2.1.1 Conventional Injection Devices, By Material 70

6.2.1.1.1 Glass 70

6.2.1.1.2 Plastic 70

6.2.1.2 Conventional Injection Devices, By Product 71

6.2.1.2.1 Fillable Syringes 71

6.2.1.2.2 Prefilled Syringes 72

6.2.1.3 Conventional Injection Devices, By Usability 73

6.2.1.3.1 Reusable Syringes 73

6.2.1.3.2 Disposable Syringes 73

6.2.2 Self Injection Devices 74

6.2.2.1 Needle Free Injectors (Nfi) 75

6.2.2.2 Needle Free Injectors, By Product 76

6.2.2.2.1 Fillable Needle-Free Injectors 76

6.2.2.2.2 Prefilled Needle-Free Injectors 76

6.2.2.3 Needle Free Injectors, By Technology 77

6.2.2.3.1 Jet Based Needle Free Injectors: 77

6.2.2.3.2 Spring Based Needle Free Injectors: 78

6.2.2.3.3 Laser Based Needle Free Injectors: 78

6.2.2.3.4 Vibration Based Needle Free Injectors: 78

6.2.2.4 Needle Free Injectors, By Usability 79

6.2.2.4.1 Reusable Needle-Free Injectors 79

6.2.2.4.2 Disposable Needle-Free Injectors 79

6.2.2.5 Auto Injectors 80

6.2.2.6 Auto Injectors, By Product 81

6.2.2.6.1 Fillable Auto Injectors 81

6.2.2.6.2 Pre-Filled Autoinjectors 81

6.2.2.7 Auto Injectors, By Technology 82

6.2.2.7.1 Automated Auto Injectors 82

6.2.2.7.2 Manual Auto Injectors 82

6.2.2.8 Auto Injectors, By Design 84

6.2.2.8.1 Standardized Auto Injectors 84

6.2.2.8.2 Automated Autoinjectors 84

6.2.2.9 Auto Injectors, By Usability 85

6.2.2.9.1 Reusable Autoinjectors 85

6.2.2.9.2 Disposable Autoinjectors 85

6.2.2.10 Pen Injectors 86

6.2.2.11 Pen Injectors, By Product 86

6.2.2.11.1 Single Chambered Pen Injectors 86

6.2.2.11.2 Dual Chambered Pen Injectors 87

6.2.2.12 Pen Injectors, By Design 87

6.2.2.12.1 Standard Pen Injectors 87

6.2.2.12.2 Customized Pen Injectors 88

6.2.2.13 Pen Injectors, By Usability 88

6.2.2.13.1 Reusable Pen Injectors 88

6.2.2.13.2 Disposable Pen Injectors 89

6.2.2.14 Wearable Injectors 89

6.2.2.14.1 Other Devices 90

6.3 Injectable Drug Delivery Formulation 91

6.3.1 Conventional Drug Delivery Formulations 92

6.3.1.1 Solutions 92

6.3.1.2 Reconstituted/Lyophilized Formulations 92

6.3.1.3 Suspensions 93

6.3.1.4 Emulsions 94

6.3.2 Novel Drug Delivery Formulations 96

6.3.2.1 Colloidal Dispersions 97

6.3.2.1.1 Niosomes 97

6.3.2.1.2 Liposomes 98

6.3.2.1.3 Polymeric Mixed Micelles 99

6.3.2.1.4 Nanoparticles 100

6.3.2.1.5 Nanosuspensions 100

6.3.2.1.6 Nanoemulsions/Microemulsions 101

6.3.2.1.7 Solid Lipid Nanoparticles 102

6.3.2.2 Microparticles 103

6.3.2.2.1 Microspheres 103

6.3.2.2.2 Microcapsules 104

6.3.2.3 Long Acting Injection Formulation 105

7 Asia-Pacific Injectable Drug Delivery Market, By Application 107

7.1 Overview 108

7.2 Asia-Pacific Injectable Drug Delivery Market, By Application 109

7.3 Hormonal Disorders 110

7.3.1 Injectable Drugs For Diabetes 110

7.3.2 Injectable Drugs For Anemia 111

7.3.3 Injectable Drugs For Reproductive Health Disease 113

7.3.4 Injectable Drugs For Antithrombotic/Thrombolytic Therapy 114

7.3.5 Injectable Drugs For Osteoporosis 114

7.3.6 Injectable Drugs For Growth Hormone Disorders (Ghd) 115

7.4 Oncology 117

7.5 Autoimmune Diseases 119

7.5.1 Injectable Drugs For Rheumatoid Arthritis 119

7.5.2 Injectable Drugs For Multiple Sclerosis 120

7.5.3 Injectable Drugs For Crohn'S Diseases 121

7.5.4 Injectable Drugs For Psoriasis 122

7.5.5 Injectable Drugs For Other Autoimmune Diseases 123

7.6 Orphan Disease 124

7.7 Other Applications 126

7.7.1 Injectable Drugs For Pain Management 126

7.7.2 Injectable Drugs For Allergy Treatment 127

7.7.3 Injectable Drugs For Aesthetic Treatments 128

7.7.4 Injectable Drugs For Hepatitis C 129

7.7.5 Injectable Drugs For Hemophilia 130

8 Asia-Pacific Injectable Drug Delivery Market, By Usage Pattern 132

8.1 Overview 133

8.2 Curative Care 134

8.3 Immunizations 135

8.4 Other Usage Pattern 136

9 Asia-Pacific Injectable Drug Delivery Market, By Mode Of Administration 137

9.1 Overview 138

9.2 Skin 139

9.3 Circulatory/ Muskoskeletal 139

9.4 Organs 140

9.5 Central Nervous System 141

10 Asia-Pacific Injectable Drug Delivery Market, By End User 142

10.1 Overview 143

10.2 Hospitals And Clinics 145

10.3 Home Healthcare Settings 145

10.4 Research Laboratories 145

10.5 Pharmaceutical And Biotechnological Companies 146

10.6 Other End Users 147

11 Asia-Pacific Injectable Drug Delivery Market, By Distribution Channel 148

11.1 Overview 149

11.1.1 Hospital Pharmacy 150

11.1.2 Pharmacy Stores 150

11.1.3 Direct Tender 150

11.1.4 Online Pharmacy 150

12 Asia-Pacific Injectable Drug Dilivery Market By Geography 152

12.1 Asia-Pacific 152

12.1.1 Japan Injectable Drug Delivery Market 171

12.1.2 China Injectable Drug Delivery Market 187

12.1.3 India Injectable Drug Delivery Market 202

12.1.4 South Korea Injectable Drug Delivery Market 217

12.1.5 Australia Injectable Drug Delivery Market 232

12.1.6 Thailand Injectable Drug Delivery Market 247

12.1.7 Malaysia Injectable Drug Delivery Market 263

12.1.8 Singapore Injectable Drug Delivery Market 278

12.1.9 Indonesia Injectable Drug Delivery Market 293

12.1.10 Phillippines Injectable Drug Delivery Market 308

12.1.11 Rest Of Asia-Pacific Injectable Drug Delivery Market 323

13 Asia-Pacific Injectable Drug Delivery Market, Company Share 324

13.1 Company Share Analysis: Asia-Pacific 324

14 Company Profiles 325

14.1 Becton, Dickinson And Company 325

14.1.1 Company Overview 325

14.1.1.1 Drivers Explained 326

14.1.1.2 Weaknesses Explained 326

14.1.1.3 Oppurtunities Explained 327

14.1.1.4 Threats Explained 327

14.1.2 Product Portfolio 328

14.1.3 Recent Developments 329

14.2 Pfizer 330

14.2.1 Company Overview 330

14.2.1.1 Drivers Explained 331

14.2.1.2 Weaknesses Explained 332

14.2.1.3 Oppurtunities Explained 332

14.2.1.4 Threats Explained 333

14.2.2 Product Portfolio 334

14.2.3 Recent Developments 335

14.3 Baxter International 336

14.3.1 Company Overview 336

14.3.1.1 Drivers Explained 337

14.3.1.2 Weaknesses Explained 338

14.3.1.3 Oppurtunities Explained 338

14.3.1.4 Threats Explained 339

14.3.2 Product Portfolio 340

14.3.3 Recent Developments 341

14.4 Gerresheimer Ag 342

14.4.1 Company Overview 342

14.4.2 Product Portfolio 343

14.4.3 Recent Developments 343

14.5 Schott Ag Inc. 344

14.5.1 Company Overview 344

14.5.2 Product Portfolio 345

14.5.3 Recent Developments 345

14.6 Alkermes Inc. 346

14.6.1 Company Overview 346

14.6.2 Product Portfolio 347

14.6.3 Recent Developments 347

14.7 Antares Pharma 348

14.7.1 Company Overview 348

14.7.2 Product Portfolio 349

14.7.3 Recent Developments 349

14.8 Bespak (Subsidiary Of Consort Medical Company) 351

14.8.1 Company Overview 351

14.8.2 Product Portfolio 352

14.8.3 Recent Developments 352

14.9 Elcam Medical 353

14.9.1 Company Overview 353

14.9.2 Product Portfolio 353

14.9.3 Recent Developments 353

14.10 Eli Lilly And Company 354

14.10.1 Company Overview 354

14.10.1.1 Drivers Explained 355

14.10.1.2 Weaknesses Explained 356

14.10.1.3 Oppurtunities Explained 356

14.10.1.4 Threats Explained 357

14.10.2 Product Portfolio 358

14.10.3 Recent Developments 359

14.11 Haselmeier 360

14.11.1 Company Overview 360

14.11.2 Product Portfolio 360

14.11.3 Recent Developments 361

14.12 Mylan N.V. 362

14.12.1 Company Overview 362

14.12.2 Product Portfolio 362

14.12.3 Recent Developments 363

14.13 Novo Nordisk 364

14.13.1 Company Overview 364

14.13.2 Product Portfolio 365

14.13.3 Recent Developments 366

14.14 Owen Mumford Ltd 367

14.14.1 Company Overview 367

14.14.2 Product Portfolio 368

14.14.3 Recent Developments 368

14.15 Sandoz International Gmbh 369

14.15.1 Company Overview 369

14.15.2 Product Portfolio 370

14.15.3 Recent Developments 370

14.16 Sanofi 371

14.16.1 Company Overview 371

14.16.2 Product Portfolio 372

14.16.3 Recent Developments 373

14.17 Terumo Corporation 374

14.17.1 Company Overview 374

14.17.2 Product Portfolio 375

14.17.3 Recent Developments 375

14.18 Teva Pharmaceutical 377

14.18.1 Company Overview 377

14.18.1.1 Drivers Explained 378

14.18.1.2 Weaknesses Explained 378

14.18.1.3 Oppurtunities Explained 379

14.18.1.4 Threats Explained 380

14.18.2 Product Portfolio 381

14.18.3 Recent Developments 382

14.19 West Pharmaceutical Services, Inc 383

14.19.1 Company Overview 383

14.19.2 Product Portfolio 384

14.19.3 Recent Developments 385

14.20 Ypsomed Holding Ag 386

14.20.1 Company Overview 386

14.20.2 Product Portfolio 387

14.20.3 Recent Developments 387

15 Related Reports 388

?


List Of Figure

List Of Figures

Figure 1 Asia-Pacific Injectable Drug Delivery Market: Segmentation 37

Figure 2 Asia-Pacific Injectable Drug Delivery Market: Geographic Scope 38

Figure 3 Asia-Pacific Injectable Drug Delivery Market: Data Triangulation 40

Figure 4 Asia-Pacific Injectable Drug Delivery Market: Research Snapshot 41

Figure 5 Asia-Pacific Injectable Drug Delivery Market: Bottom Up Approach 42

Figure 6 Asia-Pacific Injectable Drug Delivery Market: Top Down Approach 42

Figure 7 Asia-Pacific Injectable Drug Delivery Market: Interview Demographics 43

Figure 8 Figure: Drivers, Restraints, Opportunities, And Challenges Of The Injectable Drug Delivery Market 46

Figure 9 Number Of Needlestick Injuries 51

Figure 10 Technological Development And Increasing Prevalence Of Chronic Diseases Are Expected To Drive The Market For Injectable Drug Delivery In The Forecast Period 2018 To 2025 62

Figure 11 Injectable Drug Delivery Formulation Market Segment Is Expected To Account For The Largest Share Of The Asia-Pacific Injectable Drug Delivery Market In 2018 & 2025 63

Figure 12 North America Is The Highest Growing And Most Profitable Revenue Pockets For Injectable Drug Delivery Manufacturers In The Forecast Period To 2025 64

Figure 13 Asia-Pacific Injectable Drug Delivery Market: By Type, Snapshot 2016 66

Figure 14 Asia-Pacific Injectable Drug Delivery Market: By Application, Snapshot 2017 108

Figure 15 Asia-Pacific Injectable Drug Delivery Market: By Usage Pattern, Snapshot 2017 133

Figure 16 Asia-Pacific Injectable Drug Delivery Market: By Mode Of Administration, Snapshot 2017 138

Figure 17 Asia-Pacific Injectable Drug Delivery Market Dominated By Hospital And Cliinics Segment 143

Figure 18 Asia-Pacific Injectable Drug Deliverymarket: By End-User, Snapshot 2017 144

Figure 19 Asia-Pacific Injectable Drug Delivery Market: By Distribution Channel, Snapshot 2017 149

Figure 20 Asia-Pacific Injectable Drug Delivery Market Snapshot (2017) 152

Figure 21 Asia-Pacific Injectable Drug Delivery Market: Company Share 2017 (%) 324

Figure 22 Becton, Dickinson And Company: Swot (Strength, Weakness, Opportunities And Threats) 325

Figure 23 Becton, Dickinsom And Company: Revenue Analysis 328

Figure 24 Pfizer, Inc.: Swot (Strength, Weakness, Opportunities And Threats) 330

Figure 25 Pfizer, Inc.: Revenue Analysis 333

Figure 26 Baxter International Inc.: Swot (Strength, Weakness, Opportunities And Threats) 336

Figure 27 Baxter International, Inc.: Revenue Analysis 340

Figure 28 Gerresheimer Ag: Revenue Analysis 342

Figure 29 Schott Ag Inc.: Revenue Analysis 344

Figure 30 Alkermes Inc.: Revenue Analysis 346

Figure 31 Antares Pharma: Revenue Analysis 348

Figure 32 Bespak: Revenue Analysis 351

Figure 33 Elcam Medical: Revenue Analysis 353

Figure 34 Eli Lilly And Company: Swot (Strength, Weakness, Opportunities And Threats) 354

Figure 35 Eli Lilly And Company: Revenue Analysis 358

Figure 36 Haselmeier: Revenue Analysis 360

Figure 37 Mylan N.V.: Revenue Analysis 362

Figure 38 Novo Nordisk: Revenue Analysis 364

Figure 39 Owen Mumford Ltd: Revenue Analysis 367

Figure 40 Sandoz International Gmbh: Revenue Analysis 369

Figure 41 Sanofi: Revenue Analysis 371

Figure 42 Terumo Corporation: Revenue Analysis 374

Figure 43 Teva Pharmaceutical: Swot (Strength, Weakness, Opportunities And Threats) 377

Figure 44 Teva Pharmaceutical: Revenue Analysis 381

Figure 45 West Pharmaceutical Services, Inc: Revenue Analysis 384

Figure 46 Ypsomed Holding Ag: Revenue Analysis 386

Licence Rights

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies


Companies

Baxter International, Inc.,

Becton Dickinson and Company,

Gerresheimer AG,

Pfizer, Inc.,

Schott AG,

Alkermes Plc.,

Eli Lilly and Company,

Sandoz,

Terumo Corporation,

Teva Pharmaceuticals Industries Ltd.

Ypsomed,

Bespak

Asia-Pacific injectable drug delivery market is expected to reach USD 220,922.25 million by 2025 from USD 67,319.56 million in 2017, at a CAGR of 13.9% in the forecast period 2018 to 2025.

The major factors contributing to the growth of the market includes factors such rising cases of chronic diseases and due to rising demand of self-injection devices. On the other hand needle stick injuries and infections may hinder the growth of the market.

The key market players for Asia-Pacific injectable drug delivery market are listed below:

Baxter International, Inc.,

Becton Dickinson and Company,

Gerresheimer AG,

Pfizer, Inc.,

Schott AG,

Alkermes Plc.,

Eli Lilly and Company,

Sandoz,

Terumo Corporation,

Teva Pharmaceuticals Industries Ltd.

Ypsomed,

Bespak

The market is further segmented into:

Type

Usage Pattern

End-User

Mode of Administration

Distribution Channel

Application

Geography

The Asia-Pacific injectable drug delivery market is segmented on the basis of type, portability, type, product type, and application, and usage pattern, mode of administration, end user, distribution channel, and geography. The report provides data for 2016 to 2025, 2017 being the current year while 2018 to 2025 is the forecast period for the report.

The Asia-Pacific injectable drug delivery market is segmented based on type into two notable segments; injectable drug delivery device and injectable drug delivery formulation. Injectable drug delivery device market is segmented into conventional injection devices and self-injection devices. The injectable drug delivery formulation is segmented into conventional drug delivery formulation and novel drug delivery formulation. The Injectable drug delivery market is dominated by formulations with 80.0% market share in 2018, growing at a CAGR of 14.0% and will cross USD 178,225.1 million by 2025.

On the basis of application, the market is segmented into autoimmune disease, hormonal disorders, orphan diseases, oncology and others. The autoimmune diseases segment is further sub segmented based on indications into rheumatoid arthritis, multiple sclerosis, Crohn's disease, psoriasis and others. Hormonal disorders are further segmented into indications such as diabetes, antithrombotic therapy, reproductive health diseases, anemia, osteoporosis and others. The Injectable drug delivery market is dominated by hormonal disorders with 49.4% market share in 2018, growing at a CAGR of 13.7% and will cross USD 107,631.3 million by 2025. However, oncology segment is expected to grow at the highest CAGR of 15.0% in the forecast period, and is expected to reach USD 51,374.1 million in 2025 from USD 14,319.8 million in 2017

On the basis of usage pattern, the market is segmented into curative care, immunization and other usage pattern. The Injectable drug delivery market is dominated by curative care with 94.2% market share in 2018, growing at a CAGR of 13.9% and will cross USD 209,048.6 million by 2025.

On the basis of mode of administration, the market is segmented into skin, circulatory/muskoskeletal, organs and central nervous system. The Injectable drug delivery market is dominated by skin with 50.4% market share in 2018, growing at a CAGR of 14.2% and will cross USD 113,780.0 million by 2025.

On the basis of end users, the market is classified into hospitals and clinics, home healthcare, research laboratories, pharmaceutical and biotechnological companies and others. The Injectable drug delivery market is dominated by hospitals & clinics with 58.0% market share in 2018, growing at a CAGR of 14.0% and will cross USD 129,566.3 million by 2025. However, home healthcare settings segment is expected to grow at the highest CAGR of 15.2% in the forecast period, and is expected to reach USD 44,906.7 million in 2025 from USD 12,286.6 million in 2017

On the basis of distribution channel, the market is classified into hospital pharmacies, pharmacy store, and direct tender and online pharmacy. The Injectable drug delivery market is dominated by direct tenders with 75.5% market share in 2018, growing at a CAGR of 14.2% and will cross USD 170,166.5 million by 2025. However, pharmacy stores segment is expected to grow at the highest CAGR of 14.9% in the forecast period, and is expected to reach USD 28,274.5 million in 2025 from USD 7,975.8 million in 2017.

Based on geography, the Asia-Pacific injectable drug delivery market is segmented into geographical regions, such as,

Japan

China

India

South Korea

Australia

Thailand

Malaysia

Singapore

Indonesia

Taiwan

Rest of APAC

Covered in this report

The report covers the present scenario and the growth prospects of the Asia-Pacific injectable drug delivery market for 2018-2025. To calculate the market size, the report considers the revenue generated from the sales of the web conferencing and unified communication and collaboration (UC&C) and video conferencing, secondary resources and doing in-depth company share analysis of major 10 players in the market.

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

READ MORE

Scope

Table Of Contents

1 Introduction 32

1.1 Overview Of Asia-Pacific Injectable Drug Delivery Market 32

1.2 Currency And Pricing 33

1.3 Limitation 33

1.4 Markets Covered 34

2 Market Segmentation 37

2.1 Markets Covered 37

2.2 Geographic Scope 38

2.3 Years Considered For The Study 39

2.4 Currency And Pricing 39

2.5 Research Methodology 40

2.6 Primary Interviews With Key Opinion Leaders 43

2.7 Secondary Sources 44

2.8 Assumptions 44

3 Market Overview 45

3.1 Drivers 47

3.1.1 Rising Cases Of Chronic Diseases 47

3.1.2 Rising Demand Of Self-Injection Devices 49

3.1.3 Growth Of Biologics Market 49

3.1.4 Technological Advancements And Innovations In Drug Delivery Market 50

3.2 Restraints 51

3.2.1 Needlestick Injuries And Infections 51

3.2.2 High Cost Of Development 52

3.2.3 Strict Regulatory Framework 53

3.3 Opportunity 54

3.3.1 Increasing Demand For Generic And Biosimilar Drugs 54

3.3.1.1 Generics 54

3.3.1.2 Biosimilars 54

3.3.2 Increasing Demand For Contraceptive Injectables 55

3.3.3 Increasing Demand For Self-Administration Of Drugs 56

3.4 Challenges 57

3.4.1 Alternative Route Of Drug Administration 57

3.4.2 Product Recall 58

3.4.3 Stability Of Products 58

3.4.4 Sterility Of Injections 59

4 Executive Summary 60

5 Premium Insights 62

6 Asia-Pacific Injectable Drug Delivery Market, By Type 65

6.1 Overview 66

6.2 Injectable Drug Delivery Devices 67

6.2.1 Conventional Injection Devices 68

6.2.1.1 Conventional Injection Devices, By Material 70

6.2.1.1.1 Glass 70

6.2.1.1.2 Plastic 70

6.2.1.2 Conventional Injection Devices, By Product 71

6.2.1.2.1 Fillable Syringes 71

6.2.1.2.2 Prefilled Syringes 72

6.2.1.3 Conventional Injection Devices, By Usability 73

6.2.1.3.1 Reusable Syringes 73

6.2.1.3.2 Disposable Syringes 73

6.2.2 Self Injection Devices 74

6.2.2.1 Needle Free Injectors (Nfi) 75

6.2.2.2 Needle Free Injectors, By Product 76

6.2.2.2.1 Fillable Needle-Free Injectors 76

6.2.2.2.2 Prefilled Needle-Free Injectors 76

6.2.2.3 Needle Free Injectors, By Technology 77

6.2.2.3.1 Jet Based Needle Free Injectors: 77

6.2.2.3.2 Spring Based Needle Free Injectors: 78

6.2.2.3.3 Laser Based Needle Free Injectors: 78

6.2.2.3.4 Vibration Based Needle Free Injectors: 78

6.2.2.4 Needle Free Injectors, By Usability 79

6.2.2.4.1 Reusable Needle-Free Injectors 79

6.2.2.4.2 Disposable Needle-Free Injectors 79

6.2.2.5 Auto Injectors 80

6.2.2.6 Auto Injectors, By Product 81

6.2.2.6.1 Fillable Auto Injectors 81

6.2.2.6.2 Pre-Filled Autoinjectors 81

6.2.2.7 Auto Injectors, By Technology 82

6.2.2.7.1 Automated Auto Injectors 82

6.2.2.7.2 Manual Auto Injectors 82

6.2.2.8 Auto Injectors, By Design 84

6.2.2.8.1 Standardized Auto Injectors 84

6.2.2.8.2 Automated Autoinjectors 84

6.2.2.9 Auto Injectors, By Usability 85

6.2.2.9.1 Reusable Autoinjectors 85

6.2.2.9.2 Disposable Autoinjectors 85

6.2.2.10 Pen Injectors 86

6.2.2.11 Pen Injectors, By Product 86

6.2.2.11.1 Single Chambered Pen Injectors 86

6.2.2.11.2 Dual Chambered Pen Injectors 87

6.2.2.12 Pen Injectors, By Design 87

6.2.2.12.1 Standard Pen Injectors 87

6.2.2.12.2 Customized Pen Injectors 88

6.2.2.13 Pen Injectors, By Usability 88

6.2.2.13.1 Reusable Pen Injectors 88

6.2.2.13.2 Disposable Pen Injectors 89

6.2.2.14 Wearable Injectors 89

6.2.2.14.1 Other Devices 90

6.3 Injectable Drug Delivery Formulation 91

6.3.1 Conventional Drug Delivery Formulations 92

6.3.1.1 Solutions 92

6.3.1.2 Reconstituted/Lyophilized Formulations 92

6.3.1.3 Suspensions 93

6.3.1.4 Emulsions 94

6.3.2 Novel Drug Delivery Formulations 96

6.3.2.1 Colloidal Dispersions 97

6.3.2.1.1 Niosomes 97

6.3.2.1.2 Liposomes 98

6.3.2.1.3 Polymeric Mixed Micelles 99

6.3.2.1.4 Nanoparticles 100

6.3.2.1.5 Nanosuspensions 100

6.3.2.1.6 Nanoemulsions/Microemulsions 101

6.3.2.1.7 Solid Lipid Nanoparticles 102

6.3.2.2 Microparticles 103

6.3.2.2.1 Microspheres 103

6.3.2.2.2 Microcapsules 104

6.3.2.3 Long Acting Injection Formulation 105

7 Asia-Pacific Injectable Drug Delivery Market, By Application 107

7.1 Overview 108

7.2 Asia-Pacific Injectable Drug Delivery Market, By Application 109

7.3 Hormonal Disorders 110

7.3.1 Injectable Drugs For Diabetes 110

7.3.2 Injectable Drugs For Anemia 111

7.3.3 Injectable Drugs For Reproductive Health Disease 113

7.3.4 Injectable Drugs For Antithrombotic/Thrombolytic Therapy 114

7.3.5 Injectable Drugs For Osteoporosis 114

7.3.6 Injectable Drugs For Growth Hormone Disorders (Ghd) 115

7.4 Oncology 117

7.5 Autoimmune Diseases 119

7.5.1 Injectable Drugs For Rheumatoid Arthritis 119

7.5.2 Injectable Drugs For Multiple Sclerosis 120

7.5.3 Injectable Drugs For Crohn'S Diseases 121

7.5.4 Injectable Drugs For Psoriasis 122

7.5.5 Injectable Drugs For Other Autoimmune Diseases 123

7.6 Orphan Disease 124

7.7 Other Applications 126

7.7.1 Injectable Drugs For Pain Management 126

7.7.2 Injectable Drugs For Allergy Treatment 127

7.7.3 Injectable Drugs For Aesthetic Treatments 128

7.7.4 Injectable Drugs For Hepatitis C 129

7.7.5 Injectable Drugs For Hemophilia 130

8 Asia-Pacific Injectable Drug Delivery Market, By Usage Pattern 132

8.1 Overview 133

8.2 Curative Care 134

8.3 Immunizations 135

8.4 Other Usage Pattern 136

9 Asia-Pacific Injectable Drug Delivery Market, By Mode Of Administration 137

9.1 Overview 138

9.2 Skin 139

9.3 Circulatory/ Muskoskeletal 139

9.4 Organs 140

9.5 Central Nervous System 141

10 Asia-Pacific Injectable Drug Delivery Market, By End User 142

10.1 Overview 143

10.2 Hospitals And Clinics 145

10.3 Home Healthcare Settings 145

10.4 Research Laboratories 145

10.5 Pharmaceutical And Biotechnological Companies 146

10.6 Other End Users 147

11 Asia-Pacific Injectable Drug Delivery Market, By Distribution Channel 148

11.1 Overview 149

11.1.1 Hospital Pharmacy 150

11.1.2 Pharmacy Stores 150

11.1.3 Direct Tender 150

11.1.4 Online Pharmacy 150

12 Asia-Pacific Injectable Drug Dilivery Market By Geography 152

12.1 Asia-Pacific 152

12.1.1 Japan Injectable Drug Delivery Market 171

12.1.2 China Injectable Drug Delivery Market 187

12.1.3 India Injectable Drug Delivery Market 202

12.1.4 South Korea Injectable Drug Delivery Market 217

12.1.5 Australia Injectable Drug Delivery Market 232

12.1.6 Thailand Injectable Drug Delivery Market 247

12.1.7 Malaysia Injectable Drug Delivery Market 263

12.1.8 Singapore Injectable Drug Delivery Market 278

12.1.9 Indonesia Injectable Drug Delivery Market 293

12.1.10 Phillippines Injectable Drug Delivery Market 308

12.1.11 Rest Of Asia-Pacific Injectable Drug Delivery Market 323

13 Asia-Pacific Injectable Drug Delivery Market, Company Share 324

13.1 Company Share Analysis: Asia-Pacific 324

14 Company Profiles 325

14.1 Becton, Dickinson And Company 325

14.1.1 Company Overview 325

14.1.1.1 Drivers Explained 326

14.1.1.2 Weaknesses Explained 326

14.1.1.3 Oppurtunities Explained 327

14.1.1.4 Threats Explained 327

14.1.2 Product Portfolio 328

14.1.3 Recent Developments 329

14.2 Pfizer 330

14.2.1 Company Overview 330

14.2.1.1 Drivers Explained 331

14.2.1.2 Weaknesses Explained 332

14.2.1.3 Oppurtunities Explained 332

14.2.1.4 Threats Explained 333

14.2.2 Product Portfolio 334

14.2.3 Recent Developments 335

14.3 Baxter International 336

14.3.1 Company Overview 336

14.3.1.1 Drivers Explained 337

14.3.1.2 Weaknesses Explained 338

14.3.1.3 Oppurtunities Explained 338

14.3.1.4 Threats Explained 339

14.3.2 Product Portfolio 340

14.3.3 Recent Developments 341

14.4 Gerresheimer Ag 342

14.4.1 Company Overview 342

14.4.2 Product Portfolio 343

14.4.3 Recent Developments 343

14.5 Schott Ag Inc. 344

14.5.1 Company Overview 344

14.5.2 Product Portfolio 345

14.5.3 Recent Developments 345

14.6 Alkermes Inc. 346

14.6.1 Company Overview 346

14.6.2 Product Portfolio 347

14.6.3 Recent Developments 347

14.7 Antares Pharma 348

14.7.1 Company Overview 348

14.7.2 Product Portfolio 349

14.7.3 Recent Developments 349

14.8 Bespak (Subsidiary Of Consort Medical Company) 351

14.8.1 Company Overview 351

14.8.2 Product Portfolio 352

14.8.3 Recent Developments 352

14.9 Elcam Medical 353

14.9.1 Company Overview 353

14.9.2 Product Portfolio 353

14.9.3 Recent Developments 353

14.10 Eli Lilly And Company 354

14.10.1 Company Overview 354

14.10.1.1 Drivers Explained 355

14.10.1.2 Weaknesses Explained 356

14.10.1.3 Oppurtunities Explained 356

14.10.1.4 Threats Explained 357

14.10.2 Product Portfolio 358

14.10.3 Recent Developments 359

14.11 Haselmeier 360

14.11.1 Company Overview 360

14.11.2 Product Portfolio 360

14.11.3 Recent Developments 361

14.12 Mylan N.V. 362

14.12.1 Company Overview 362

14.12.2 Product Portfolio 362

14.12.3 Recent Developments 363

14.13 Novo Nordisk 364

14.13.1 Company Overview 364

14.13.2 Product Portfolio 365

14.13.3 Recent Developments 366

14.14 Owen Mumford Ltd 367

14.14.1 Company Overview 367

14.14.2 Product Portfolio 368

14.14.3 Recent Developments 368

14.15 Sandoz International Gmbh 369

14.15.1 Company Overview 369

14.15.2 Product Portfolio 370

14.15.3 Recent Developments 370

14.16 Sanofi 371

14.16.1 Company Overview 371

14.16.2 Product Portfolio 372

14.16.3 Recent Developments 373

14.17 Terumo Corporation 374

14.17.1 Company Overview 374

14.17.2 Product Portfolio 375

14.17.3 Recent Developments 375

14.18 Teva Pharmaceutical 377

14.18.1 Company Overview 377

14.18.1.1 Drivers Explained 378

14.18.1.2 Weaknesses Explained 378

14.18.1.3 Oppurtunities Explained 379

14.18.1.4 Threats Explained 380

14.18.2 Product Portfolio 381

14.18.3 Recent Developments 382

14.19 West Pharmaceutical Services, Inc 383

14.19.1 Company Overview 383

14.19.2 Product Portfolio 384

14.19.3 Recent Developments 385

14.20 Ypsomed Holding Ag 386

14.20.1 Company Overview 386

14.20.2 Product Portfolio 387

14.20.3 Recent Developments 387

15 Related Reports 388

?


List Of Figure

List Of Figures

Figure 1 Asia-Pacific Injectable Drug Delivery Market: Segmentation 37

Figure 2 Asia-Pacific Injectable Drug Delivery Market: Geographic Scope 38

Figure 3 Asia-Pacific Injectable Drug Delivery Market: Data Triangulation 40

Figure 4 Asia-Pacific Injectable Drug Delivery Market: Research Snapshot 41

Figure 5 Asia-Pacific Injectable Drug Delivery Market: Bottom Up Approach 42

Figure 6 Asia-Pacific Injectable Drug Delivery Market: Top Down Approach 42

Figure 7 Asia-Pacific Injectable Drug Delivery Market: Interview Demographics 43

Figure 8 Figure: Drivers, Restraints, Opportunities, And Challenges Of The Injectable Drug Delivery Market 46

Figure 9 Number Of Needlestick Injuries 51

Figure 10 Technological Development And Increasing Prevalence Of Chronic Diseases Are Expected To Drive The Market For Injectable Drug Delivery In The Forecast Period 2018 To 2025 62

Figure 11 Injectable Drug Delivery Formulation Market Segment Is Expected To Account For The Largest Share Of The Asia-Pacific Injectable Drug Delivery Market In 2018 & 2025 63

Figure 12 North America Is The Highest Growing And Most Profitable Revenue Pockets For Injectable Drug Delivery Manufacturers In The Forecast Period To 2025 64

Figure 13 Asia-Pacific Injectable Drug Delivery Market: By Type, Snapshot 2016 66

Figure 14 Asia-Pacific Injectable Drug Delivery Market: By Application, Snapshot 2017 108

Figure 15 Asia-Pacific Injectable Drug Delivery Market: By Usage Pattern, Snapshot 2017 133

Figure 16 Asia-Pacific Injectable Drug Delivery Market: By Mode Of Administration, Snapshot 2017 138

Figure 17 Asia-Pacific Injectable Drug Delivery Market Dominated By Hospital And Cliinics Segment 143

Figure 18 Asia-Pacific Injectable Drug Deliverymarket: By End-User, Snapshot 2017 144

Figure 19 Asia-Pacific Injectable Drug Delivery Market: By Distribution Channel, Snapshot 2017 149

Figure 20 Asia-Pacific Injectable Drug Delivery Market Snapshot (2017) 152

Figure 21 Asia-Pacific Injectable Drug Delivery Market: Company Share 2017 (%) 324

Figure 22 Becton, Dickinson And Company: Swot (Strength, Weakness, Opportunities And Threats) 325

Figure 23 Becton, Dickinsom And Company: Revenue Analysis 328

Figure 24 Pfizer, Inc.: Swot (Strength, Weakness, Opportunities And Threats) 330

Figure 25 Pfizer, Inc.: Revenue Analysis 333

Figure 26 Baxter International Inc.: Swot (Strength, Weakness, Opportunities And Threats) 336

Figure 27 Baxter International, Inc.: Revenue Analysis 340

Figure 28 Gerresheimer Ag: Revenue Analysis 342

Figure 29 Schott Ag Inc.: Revenue Analysis 344

Figure 30 Alkermes Inc.: Revenue Analysis 346

Figure 31 Antares Pharma: Revenue Analysis 348

Figure 32 Bespak: Revenue Analysis 351

Figure 33 Elcam Medical: Revenue Analysis 353

Figure 34 Eli Lilly And Company: Swot (Strength, Weakness, Opportunities And Threats) 354

Figure 35 Eli Lilly And Company: Revenue Analysis 358

Figure 36 Haselmeier: Revenue Analysis 360

Figure 37 Mylan N.V.: Revenue Analysis 362

Figure 38 Novo Nordisk: Revenue Analysis 364

Figure 39 Owen Mumford Ltd: Revenue Analysis 367

Figure 40 Sandoz International Gmbh: Revenue Analysis 369

Figure 41 Sanofi: Revenue Analysis 371

Figure 42 Terumo Corporation: Revenue Analysis 374

Figure 43 Teva Pharmaceutical: Swot (Strength, Weakness, Opportunities And Threats) 377

Figure 44 Teva Pharmaceutical: Revenue Analysis 381

Figure 45 West Pharmaceutical Services, Inc: Revenue Analysis 384

Figure 46 Ypsomed Holding Ag: Revenue Analysis 386

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Companies

Baxter International, Inc.,

Becton Dickinson and Company,

Gerresheimer AG,

Pfizer, Inc.,

Schott AG,

Alkermes Plc.,

Eli Lilly and Company,

Sandoz,

Terumo Corporation,

Teva Pharmaceuticals Industries Ltd.

Ypsomed,

Bespak